Welcome to our dedicated page for Definium Therapeutics SEC filings (Ticker: DFTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Definium Therapeutics, Inc. filings document the regulatory record of a British Columbia clinical-stage biopharmaceutical company traded on Nasdaq as DFTX. Current reports on Form 8-K disclose financial results, corporate highlights, investor-presentation materials, and clinical and commercial updates for DT120 ODT in psychiatric indications.
Definitive proxy materials cover annual general and special meeting matters, including director elections, auditor appointment, compensation governance, and shareholder voting procedures. Other filings record board composition changes, non-employee director compensation, stock option awards, indemnity arrangements, and the company’s corporate identity following its former name, Mind Medicine (MindMed) Inc.
Definium Therapeutics, Inc. (DFTX) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its DT120 (lysergide) orally disintegrating tablet (ODT) for the treatment of major depressive disorder (MDD). This is the second Breakthrough Therapy designation for the DT120 program, following an earlier designation in generalized anxiety disorder (GAD).
The designation is based on results from the Phase 3 Emerge study, where a single 100 µg dose of DT120 ODT achieved a statistically significant 8.1‑point placebo‑adjusted improvement in Montgomery‑Åsberg Depression Rating Scale (MADRS) total score at Week 6 (p<0.0001), with efficacy described as durable through Week 12. DT120 ODT is a proprietary, pharmaceutically optimized LSD formulation using Zydis ODT fast‑dissolve technology, intended to improve onset, bioavailability and tolerability.
Definium highlights the large unmet need in MDD, where more than 21 million U.S. adults experience a major depressive episode annually and fewer than one‑third achieve remission with first‑line treatments, and notes a multi‑layered intellectual property strategy to protect the DT120 ODT franchise.
Definium Therapeutics, Inc. (DFTX) reported that Chief Executive Officer and director Robert Barrow received an award of 40,000 common shares on September 2, 2026, representing the first tranche of performance share units originally granted effective February 3, 2026, which vest based on specified clinical and regulatory milestones. This amount also includes 417 shares acquired under the company’s 2024 Employee Share Purchase Plan on August 17, 2026.
On September 3, 2026, Barrow sold 19,023 common shares to satisfy withholding tax obligations related to the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. The reported weighted average sales price was $37.94 per share, with individual trades executed between $37.46 and $38.94 per share.
Definium Therapeutics, Inc. (DFTX) is the subject of a notice that shareholder Robert B. Barrow intends to sell 19,023 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $718,144.88 as of the planned sale date of September 3, 2026.
These shares are tied to Performance Stock Units acquired from the issuer as compensation for services rendered on September 3, 2026, and follow a prior sale of 29,208 shares for $1,230,533.04 during the past three months.
Definium Therapeutics, Inc. investor Commodore Capital and related filers report beneficial ownership of 2,410,000 Common Shares, including shares underlying a pre-funded warrant, as of June 30, 2026. This represents 1.8% of the outstanding Common Shares of Definium Therapeutics, Inc.
The position consists of 2,000,000 Common Shares and 410,000 Common Shares that each filer has the right to acquire through exercise of a pre-funded warrant. Voting and dispositive power over all 2,410,000 shares is reported on a shared basis, with no sole voting or dispositive power. The ownership percentage is based on 134,365,950 Common Shares outstanding as of June 30, 2026, plus the 410,000 shares issuable upon exercise of the pre-funded warrant.
Definium Therapeutics, Inc. has a significant shareholder, Driehaus Capital Management LLC (DCM), which reported ownership of 6,845,276 shares of Definium common stock on a Schedule 13G/A. This position represented 5.36% of the outstanding common stock as of June 30, 2026.
DCM stated that its percentage interest was 5.36% as of June 30, 2026, compared with 6.64% as of December 31, 2025. All reported shares are held in numerous client accounts managed by DCM on a fully discretionary basis. DCM reported shared voting power and shared dispositive power over 6,845,276 shares, with no sole voting or dispositive power. The issuer changed its name from Mind Medicine (MindMed), Inc. to Definium Therapeutics, Inc. on January 12, 2026.
Definium Therapeutics, Inc. reported that Chief Executive Officer Robert Barrow acquired 375,000 common shares as a grant/award at a price of $0.0000 per share. The award represents the second tranche of performance share units granted effective March 12, 2025, and remains subject to vesting based on continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Barrow directly holds 1,473,246 common shares.
Karlin Daniel reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Medical Officer Daniel Karlin received a grant of 100,000 Common Shares at a price of $0.00 per share. These shares represent the second tranche of performance share units originally granted effective March 12, 2025, and remain subject to vesting based on continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement. Following this award, Karlin directly holds 603,282 Common Shares.
Definium Therapeutics, Inc. reported that Chief Legal Officer Mark Sullivan acquired 62,500 common shares on August 12, 2026, at a stated price of $0.00 per share, increasing his direct holdings to 383,071 shares. According to the award terms, these shares represent the second tranche of performance share units granted effective March 12, 2025 and remain subject to vesting based on continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones.
Definium Therapeutics, Inc. reported that Chief Commercial Officer Matthew T. Wiley acquired 62,500 common shares as a grant/award. According to the award terms, these shares represent the second tranche of performance share units granted effective March 17, 2025 and remain subject to vesting based on continued employment through March 17, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Wiley holds 237,133 common shares directly.
Roberts Brandi reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Financial Officer Brandi Roberts received a grant of 62,500 Common Shares on August 12, 2026, at a stated price of $0.00 per share as a grant or award. After this award, Roberts directly holds 271,987 Common Shares. The shares represent the second tranche of performance share units originally granted effective June 2, 2025, and remain subject to vesting based on continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones.